Skip to main content
Delfa

← All assets

Brexpiprazole

7 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

7

Ongoing

1

Recruiting

1

Completed

6

Sites

150

Countries

14

Endpoints

47

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 47 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2/3
1
Phase 3
5
Not applicable
1

Trials by status

Recruiting
1
Completed
6

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
30
Safety / tolerability / PK
8
Other clinical outcomes
6
Other (unclassified)
2
Disease progression
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 0 of 47 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

No normalized metric codes are available for this asset.

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

7 of 7

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT01862640A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Brexpiprazole

Alzheimer’s disease

Alzheimer's diseasePh 3Completed85Mar 201710results
NCT01922258Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole

Alzheimer’s disease

Alzheimer's diseasePh 3Completed70Mar 20176results
NCT03548584A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole

Alzheimer’s disease

Alzheimer's diseasePh 3Completed1May 202210results
NCT03620981Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole

Alzheimer’s disease

Alzheimer's diseasePh 2/3Completed1Apr 20231results
NCT03594123A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole

Alzheimer’s disease

Study partner/caregiver requiredPh 3Completed1Sep 20224results
NCT03724942Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole

Alzheimer’s disease

Age 55-89Ph 3Completed1Dec 20211results
NCT06875986REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

Brexpiprazole

Alzheimer’s disease

Alzheimer's diseaseNot applicableRecruiting1Sep 2027-

Showing 1-7 of 7 trials